These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 12949548)

  • 21. Value creation and sharing among universities, biotechnology and pharma.
    Edwards MG; Murray F; Yu R
    Nat Biotechnol; 2003 Jun; 21(6):618-24. PubMed ID: 12776145
    [No Abstract]   [Full Text] [Related]  

  • 22. Investing in nanotechnology.
    Paull R; Wolfe J; Hébert P; Sinkula M
    Nat Biotechnol; 2003 Oct; 21(10):1144-7. PubMed ID: 14520393
    [No Abstract]   [Full Text] [Related]  

  • 23. European markets target foreign biotechs.
    Louët S
    Nat Biotechnol; 2003 Jul; 21(7):719. PubMed ID: 12833075
    [No Abstract]   [Full Text] [Related]  

  • 24. KS Biomedix licenses TransMID brain cancer product to Nycomed in European collaboration.
    Expert Rev Anticancer Ther; 2002 Oct; 2(5):481. PubMed ID: 12382509
    [No Abstract]   [Full Text] [Related]  

  • 25. Michigan's next wave of biopharmaceutical entrepreneurship.
    Kerppola R; van de Walle M; Surine S
    Nat Biotechnol; 2003 Sep; 21(9):1109-11. PubMed ID: 12949575
    [No Abstract]   [Full Text] [Related]  

  • 26. A very firm handshake: biotech's growing negotiating power.
    Thiel KA
    Nat Biotechnol; 2005 Oct; 23(10):1221-6. PubMed ID: 16211058
    [No Abstract]   [Full Text] [Related]  

  • 27. Never again.
    Scott C
    Nat Biotechnol; 2010 Feb; 28(2):131. PubMed ID: 20139946
    [No Abstract]   [Full Text] [Related]  

  • 28. Value drivers in licensing deals.
    Arnold K; Coia A; Saywell S; Smith T; Minick S; Löffler A
    Nat Biotechnol; 2002 Nov; 20(11):1085-9. PubMed ID: 12410249
    [No Abstract]   [Full Text] [Related]  

  • 29. Exiting this year and into the next.
    Nat Biotechnol; 2005 Dec; 23(12):1451. PubMed ID: 16333272
    [No Abstract]   [Full Text] [Related]  

  • 30. Selling out.
    Martin JF
    Nat Biotechnol; 2010 Apr; 28(4):315-7. PubMed ID: 20383912
    [No Abstract]   [Full Text] [Related]  

  • 31. A license to print money?
    Nat Biotechnol; 2006 Jun; 24(6):593. PubMed ID: 16763570
    [No Abstract]   [Full Text] [Related]  

  • 32. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 33. Anthony Coyle.
    Coyle A
    Nat Biotechnol; 2011 Mar; 29(3):187. PubMed ID: 21390006
    [No Abstract]   [Full Text] [Related]  

  • 34. Elias Zerhouni.
    Zerhouni E
    Nat Biotechnol; 2011 Mar; 29(3):188. PubMed ID: 21390007
    [No Abstract]   [Full Text] [Related]  

  • 35. Licensing deals morph to acquisitions in seller's market.
    Moran N
    Nat Biotechnol; 2007 Jun; 25(6):609-10. PubMed ID: 17557085
    [No Abstract]   [Full Text] [Related]  

  • 36. A special biotech speculation.
    Jacobs T
    Nat Biotechnol; 2006 Jun; 24(6):622. PubMed ID: 16763586
    [No Abstract]   [Full Text] [Related]  

  • 37. Great company, bad stock.
    Jacobs T
    Nat Biotechnol; 2005 Feb; 23(2):173. PubMed ID: 15696142
    [No Abstract]   [Full Text] [Related]  

  • 38. No pain, no gain?
    Jacobs T
    Nat Biotechnol; 2005 Aug; 23(8):934. PubMed ID: 16082357
    [No Abstract]   [Full Text] [Related]  

  • 39. When your stock takes a nosedive.
    Jacobs T
    Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
    [No Abstract]   [Full Text] [Related]  

  • 40. Hidden in plain view.
    Jacobs T
    Nat Biotechnol; 2003 Jun; 21(6):603. PubMed ID: 12776141
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.